Pharma & biotech

NICE approves migraine wafer from Pfizer

The British regulatory body, NICE, has approved the wafer Vydura from Biohaven/Pfizer as a preventive measure against migraines but not as acute treatment.
The UK's health regulator NICE have given its stamp of approval to migraine treatment drug Vydura (rimegepant). It is known as Nurtec in the US and is marketed outside the country by Pfizer. | Photo: v
The UK's health regulator NICE have given its stamp of approval to migraine treatment drug Vydura (rimegepant). It is known as Nurtec in the US and is marketed outside the country by Pfizer. | Photo: v
by albert rønning-andersson, translated by christian radich hoffman

The UK National Institute for Health and Care Excellence (NICE) gives the thumbs-up to migraine treatment drug Vydura (rimegepant), sold in the US under the name of Nurtec, NICE writes in a press release. Outside the US, Pfizer is in charge of sales.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs